Interestingly, a post hoc analysis of this trial revealed that dapagliflozin altered biomarkers related to iron homeostasis, decreased hepcidin and ferritin, and increased transferrin receptor protein, showing that this drug may alleviate the state of functional iron deficiency commonly seen in patients with chronic heart failure [48]. Here, HAMP is linked to Iron deficiency anemia.